VBI Vaccines Inc.

VBI Vaccines — Technical Presentation (November 2020)

7 slides from VBI Vaccines's technical presentation, Nov 19, 2020

  1. Slide 1: VBI-1901: SNO Phase 2a Data & Clinical Update

    \ NW Uy, NS VBI VACCINES MMW a VBI-1901: SNO Phase 2a Data & Clinical Update Jeff Baxter, CEO, and David E. Anderson, Ph.D., CSO NOVEMBER 19 2020 NASDAQ: VBIV

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Certain statements in this presentation that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are forward-looking informatio

  3. Slide 3: Clinical Outcomes From Ongoing Phase 1/2a Clinical Study of VBI-1901 in Recurrent GBM Patients

    Clinical Outcomes From Ongoing Phase 1/2a Clinical Study of VBI-1901 in Recurrent GBM Patients Phase 1 (Part A) : Dose-Escalation Phase — Recurrent GBM (any # of recurrences) Study Arm 1: Low Dose (n=6) * Enrollment completed December 2018 (n=18) 0.Aug + GM-CSF * 12-month overall survival (OS) rate

  4. Slide 4: Part 2a Tumor Responses

    es Part 2a Tumor Responses Disease Control Rate = Stable Disease (SD) + Partial Response (PR) + Complete Response (CR) VBI-1901 10g + GM-CSF Disease Control Rate : 40% (n=4/10) ‘Tumor Responses: 2 Partial Response (PRs) Y_ 2Stable Disease (SD) VBI-1901 10pg+ASO1, Disease ‘Tumor Responses: Y 5 Stable

  5. Slide 5: AS01B May be Able to Overcome Deficiencies in Baseline Immunologic Fitness

    OOOO eee AS01, May be Able to Overcome Deficiencies in Baseline Immunologic Fitness Tumor responses seen with treatment of VBI-2901 + ASO1, regardless of CD4+/CD8+ ratio biomarker status, previously seen to correlate with tumor responses in VBI-1901 + GM- CSF study arm GM-CSF Arm AS01, Arm 6_ Baseli

  6. Slide 6: Conclusions

    nn eee Conclusions Summary of Data: * 9 tumor responses, including 2 partial responses, seen to-date in both Part B study arms of the ongoing Phase 1/2a clinical study of VBI-1901 in recurrent GBM patients * Disease Control Rates (DCR) of 40% and 56% observed in the VBI-1901 + GM-CSF and VBI-1901 +

  7. Slide 7: VBI Vaccines Inc. contact details

    VBI Vaccines Inc. 222 Third Street, Suite 2241 Cambridge, MA 02142 (617) 830-3031 [email protected]

VBI Vaccines — Technical Presentation (November 2020) on 6ix